Compare Bristol-Myers Squibb Co (BMY) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Bitdeer Technologies Group — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Bitdeer Technologies Group trades at $12.42 (market cap $3.01B). The key difference: Bristol-Myers Squibb Co is far larger — about 38.6× Bitdeer Technologies Group's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| BMY | BTDR | |
|---|---|---|
Market Cap | $116.30B | $3.01B |
Sector | Health | Technology |
52-Week High | $62.37 | $25.90 |
52-Week Low | $42.60 | $7.28 |
Enterprise Value | $152.24B | $4.77B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
BTDR trades at $12.13, down 8.73% over 24 hours, with technical indicators signaling a bearish trend. The stock shows strong analyst support with 9 out of 11 ratings as Buy and a consensus price target of $23.40, but fundamentals reveal challenges: negative net income margin of -26.96% and three consecutive quarterly earnings misses. Recent news highlights expansion into AI infrastructure, including a new $36 million manufacturing facility in Nevada and an AI cloud platform award in June 2026.
The outlook is mixed: bullish analyst sentiment and strategic growth in AI and mining infrastructure offer upside potential, but persistent losses, negative cash flow from operations, and high debt-to-asset ratio of 35.69% pose significant risks. Investors should weigh the company's expansion against its financial health and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
